The Impact of Epigenetic Modifications in Myeloid Malignancies.

Myeloid malignancy is a broad term encapsulating myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Initial studies into genomic profiles of these diseases have shown 2000 somatic mutations prevalent across the spectrum of myeloid blood disorders. Epigenetic mutations are emerging as critical components of disease progression, with mutations in genes controlling chromatin regulation and methylation/acetylation status. Genes such as DNA methyltransferase 3A ( DNMT3A ), ten eleven translocation methylcytosine dioxygenase 2 ( TET2 ), additional sex combs-like 1 ( ASXL1 ), enhancer of zeste homolog 2 ( EZH2 ) and isocitrate dehydrogenase 1/2 ( IDH1/2 ) show functional impact in disease pathogenesis. In this review we discuss how current knowledge relating to disease progression, mutational profile and therapeutic potential is progressing and increasing understanding of myeloid malignancies.